Catalog No. |
TD-HS739056 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Host species |
Humanized |
Isotype |
IgG1-Kappa |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
VSTM3, TIGIT, V-set and transmembrane domain-containing protein 3, VSIG9, V-set and immunoglobulin domain-containing protein 9, T-cell immunoreceptor with Ig and ITIM domains |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
Q495A1 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
BGB-A1217,CAS:2342597-93-5 |
Background |
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer. |
Note |
For research use only. Not for use in clinical or therapeutic applications. |